Carriage rates and risk factors during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11) in Tuscany, Italy: a cross-sectional study.
Adolescent
Adult
Carrier State
/ epidemiology
Child
Cross-Sectional Studies
Disease Outbreaks
Female
Homosexuality, Male
Humans
Italy
/ epidemiology
Male
Meningococcal Infections
/ epidemiology
Middle Aged
Multilocus Sequence Typing
Neisseria meningitidis, Serogroup C
/ classification
Oropharynx
/ microbiology
Polymerase Chain Reaction
Prevalence
Risk Factors
Serogroup
Sexual and Gender Minorities
/ statistics & numerical data
Young Adult
Carrier state
Cross-sectional studies
Disease outbreaks
Neisseria meninigitidis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
08 Jan 2019
08 Jan 2019
Historique:
received:
16
03
2018
accepted:
07
12
2018
entrez:
10
1
2019
pubmed:
10
1
2019
medline:
16
2
2019
Statut:
epublish
Résumé
During 2015-2016 an outbreak of invasive meningococcal disease due to N. meningitidis serogroup C ST-11 (cc11) occurred in Tuscany, Italy. The outbreak affected mainly the age group 20-30 years, men who have sex with men, and the area located between the cities of Firenze, Prato and Empoli, with discos and gay-venues associated-clusters. A cross-sectional-survey was conducted to assess the prevalence and risk factors for meningococcal-carriage, in order to address public health interventions. A convenience sample of people aged 11-45 years provided oropharyngeal swab specimens and completed questionnaires on risk factors for meningococcal carriage during a 3 months study-period, conducted either in the outbreak-area and in a control-area not affected by the outbreak (cities of Grosseto and Siena). Isolates were tested by culture plus polymerase chain reaction. Serogroup C meningococcal isolates were further characterized using multilocus sequence typing. Univariate and multivariate analyses were performed to estimate adjusted odds ratios (AORs) for meningococcal carriage. A total of 2285 oropharyngeal samples were collected. Overall, meningococcal carriage prevalence was 4.8% (n = 110), with nonencapsulated meningococci most prevalent (2.3%; n = 52). Among encapsulated meningococci, serogroup B was the most prevalent (1.8%; n = 41), followed by serogroup Y (0.5%; n = 11) and serogroup C (0.2%; n = 4); one carrier of serogroup E and one of serogroup Z, were also found (0.04%). Three individuals from the city of Empoli were found to carry the outbreak strain, C:ST-11 (cc11); this city also had the highest serogroup C carriage prevalence (0.5%). At the multivariate analyses, risk factors for meningococcal carriage were: illicit-drugs consumption (AOR 6.30; p < 0.01), active smoking (AOR 2.78; p = 0.01), disco/clubs/parties attendance (AOR 2.06; p = 0.04), being aged 20-30 years (AOR 3.08; p < 0.01), and have had same-sex intercourses (AOR 6.69; p < 0.01). A low prevalence of meningococcal serogroup C carriage in an area affected by an outbreak due to the hypervirulent N. meningitidis serogroup C ST-11 (cc11) strain was found. The city of Empoli had the highest attack-rate during the outbreak and also the highest meningococcal serogroup C carriage-prevalence due to the outbreak-strain. Multivariate analyses underlined a convergence of risk factors, which partially confirmed those observed among meningococcal outbreak-cases, and that should be considered in targeted immunization campaigns.
Sections du résumé
BACKGROUND
BACKGROUND
During 2015-2016 an outbreak of invasive meningococcal disease due to N. meningitidis serogroup C ST-11 (cc11) occurred in Tuscany, Italy. The outbreak affected mainly the age group 20-30 years, men who have sex with men, and the area located between the cities of Firenze, Prato and Empoli, with discos and gay-venues associated-clusters. A cross-sectional-survey was conducted to assess the prevalence and risk factors for meningococcal-carriage, in order to address public health interventions.
METHODS
METHODS
A convenience sample of people aged 11-45 years provided oropharyngeal swab specimens and completed questionnaires on risk factors for meningococcal carriage during a 3 months study-period, conducted either in the outbreak-area and in a control-area not affected by the outbreak (cities of Grosseto and Siena). Isolates were tested by culture plus polymerase chain reaction. Serogroup C meningococcal isolates were further characterized using multilocus sequence typing. Univariate and multivariate analyses were performed to estimate adjusted odds ratios (AORs) for meningococcal carriage.
RESULTS
RESULTS
A total of 2285 oropharyngeal samples were collected. Overall, meningococcal carriage prevalence was 4.8% (n = 110), with nonencapsulated meningococci most prevalent (2.3%; n = 52). Among encapsulated meningococci, serogroup B was the most prevalent (1.8%; n = 41), followed by serogroup Y (0.5%; n = 11) and serogroup C (0.2%; n = 4); one carrier of serogroup E and one of serogroup Z, were also found (0.04%). Three individuals from the city of Empoli were found to carry the outbreak strain, C:ST-11 (cc11); this city also had the highest serogroup C carriage prevalence (0.5%). At the multivariate analyses, risk factors for meningococcal carriage were: illicit-drugs consumption (AOR 6.30; p < 0.01), active smoking (AOR 2.78; p = 0.01), disco/clubs/parties attendance (AOR 2.06; p = 0.04), being aged 20-30 years (AOR 3.08; p < 0.01), and have had same-sex intercourses (AOR 6.69; p < 0.01).
CONCLUSIONS
CONCLUSIONS
A low prevalence of meningococcal serogroup C carriage in an area affected by an outbreak due to the hypervirulent N. meningitidis serogroup C ST-11 (cc11) strain was found. The city of Empoli had the highest attack-rate during the outbreak and also the highest meningococcal serogroup C carriage-prevalence due to the outbreak-strain. Multivariate analyses underlined a convergence of risk factors, which partially confirmed those observed among meningococcal outbreak-cases, and that should be considered in targeted immunization campaigns.
Identifiants
pubmed: 30621624
doi: 10.1186/s12879-018-3598-3
pii: 10.1186/s12879-018-3598-3
pmc: PMC6323866
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Investigateurs
Alessandra Bagnoli
(A)
Giuseppe Boncompagni
(G)
Francesco Cirpiani
(F)
Paolo Filidei
(P)
Giorgio Garofalo
(G)
Marinella Chiti
(M)
Gabriele Mazzoni
(G)
Astrid Mercone
(A)
Giovanna Mereu
(G)
Sabrina Novelli
(S)
Maria Grazia Santini
(MG)
Maurizio Spagnesi
(M)
Références
J Infect. 1999 Jul;39(1):42-8
pubmed: 10468128
Emerg Infect Dis. 2000 Jan-Feb;6(1):65-9
pubmed: 10653573
Epidemiol Infect. 1999 Dec;123(3):349-57
pubmed: 10694145
J Clin Microbiol. 2000 Apr;38(4):1638-40
pubmed: 10747157
South Med J. 2001 May;94(5):482-5
pubmed: 11372796
Eur J Clin Microbiol Infect Dis. 2001 Apr;20(4):237-42
pubmed: 11399012
J Clin Microbiol. 2002 Jan;40(1):75-9
pubmed: 11773095
South Med J. 2001 Dec;94(12):1192-4
pubmed: 11811858
Clin Infect Dis. 2003 Nov 1;37(9):1183-8
pubmed: 14557962
J Clin Microbiol. 2004 Apr;42(4):1764-5
pubmed: 15071043
J Clin Microbiol. 2005 Mar;43(3):1301-3
pubmed: 15750099
Am J Epidemiol. 2005 Jul 1;162(1):89-100
pubmed: 15961591
Epidemiol Infect. 2006 Jun;134(3):556-66
pubmed: 16238823
FEMS Microbiol Rev. 2007 Jan;31(1):52-63
pubmed: 17233635
Epidemiol Infect. 1991 Feb;106(1):133-41
pubmed: 1899646
J Infect. 2009 Feb;58(2):103-7
pubmed: 19167762
Clin Infect Dis. 2009 Apr 1;48(7):894-901
pubmed: 19231975
BMC Infect Dis. 2009 Aug 22;9:135
pubmed: 19698137
Lancet Infect Dis. 2010 Dec;10(12):853-61
pubmed: 21075057
Expert Rev Anti Infect Ther. 2011 Sep;9(9):761-74
pubmed: 21905785
Euro Surveill. 2013 Jul 11;18(28):null
pubmed: 23870094
Vaccine. 2014 Feb 26;32(10):1187-91
pubmed: 24120548
J Clin Microbiol. 2014 Jun;52(6):1901-10
pubmed: 24648565
Emerg Infect Dis. 2014 May;20(5):806-11
pubmed: 24751156
BMC Infect Dis. 2015 Jul 30;15:300
pubmed: 26223223
Hum Vaccin Immunother. 2016;12(2):467-73
pubmed: 26308192
PLoS One. 2015 Aug 31;10(8):e0135497
pubmed: 26322796
Euro Surveill. 2016;21(12):null
pubmed: 27035155
J Infect. 2016 Aug;73(2):136-44
pubmed: 27235364
PLoS One. 2016 Nov 18;11(11):e0166475
pubmed: 27861618
Emerg Infect Dis. 2017 Feb;23(2):336-339
pubmed: 28098538
Hum Vaccin Immunother. 2017 May 4;13(5):1182-1189
pubmed: 28140784
Euro Surveill. 2018 Aug;23(34):null
pubmed: 30153883
JAMA. 1980 Nov 7;244(18):2060-4
pubmed: 6776296
Scand J Infect Dis. 1993;25(3):331-9
pubmed: 8362229
J Clin Microbiol. 1995 Dec;33(12):3133-7
pubmed: 8586688
Epidemiol Infect. 1996 Oct;117(2):259-66
pubmed: 8870623
J Infect. 1997 Mar;34(2):101-5
pubmed: 9138131
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5
pubmed: 9501229